https://gskj4inhibitor.com/a-n....ovel-method-for-dige
To gauge the efficacy and protection of polyethylene glycol loxenatide (PEX168) monotherapy in type 2 diabetes (T2D) patients in China. The 3 groups had comparable demographics and baseline qualities. The HbA1c least-square mean (95% CI) change from baseline to week 24 had been greater for PEX168/100 μg (-1.02% [-1.21%, -0.83%]) and PEX168/200 μg (-1.34% [-1.54%, -1.15%]) than for placebo (-0.17% [-0.36%, 0.02%]); (superiority P .0001). The proportions of patients with less tha
Like
Comment
Share
